Compare Nuwellis Inc (NUWE) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Nuwellis Inc trades at $0.7 (market cap $2.20M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.58 (market cap $1.45B). The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is far larger — about 659.1× Nuwellis Inc's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days on average.
| NUWE | QQQE | |
|---|---|---|
Market Cap | $2.20M | $1.45B |
Volume | 121,544 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $146.65 | $124.69 |
52-Week Low | $0.68 | $96.06 |
Typical Hold Time | 26 Days | 47 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
QQQE trades at $121.89, down 0.89% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 large-cap growth stocks, reducing technology concentration compared to market-cap weighted alternatives. Recent analysis highlights QQQE's tactical appeal for diversification within tech-heavy indices.
The equal-weight methodology offers fundamental diversification benefits, though specific financial ratios are unavailable for the ETF structure. Market sentiment appears constructive with technical strength, but investors face typical ETF risks including market volatility and sector concentration despite the equal-weight approach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
